Galcanezumab CONQUERs migraine prevention

Affiliations

Comment

Uwe Reuter. Lancet Neurol. 2020 Oct.

. 2020 Oct;19(10):798-799.

doi: 10.1016/S1474-4422(20)30324-0. Epub 2020 Sep 16.

¹ Department of Neurology, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany. Electronic address: uwe.reuter@charite.de.

No abstract available

Comment on

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM, Kim BK, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC. Mulleners WM, et al. Lancet Neurol. 2020 Oct;19(10):814-825. doi: 10.1016/S1474-4422(20)30279-9. Epub 2020 Sep 16. Lancet Neurol. 2020. PMID: 32949542 Clinical Trial.